IN8bio, Inc.
INAB
$1.75
-$0.03-1.69%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -24.37% | -21.63% | -15.96% | -6.46% | -8.57% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -32.75% | -28.69% | -15.40% | -3.48% | 2.51% |
| Operating Income | 32.75% | 28.69% | 15.40% | 3.48% | -2.51% |
| Income Before Tax | 35.19% | 25.25% | 11.66% | -1.43% | -5.52% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 35.19% | 25.25% | 11.66% | -1.43% | -5.52% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 35.19% | 25.25% | 11.66% | -1.43% | -5.52% |
| EBIT | 32.75% | 28.69% | 15.40% | 3.48% | -2.51% |
| EBITDA | 35.05% | 31.04% | 16.50% | 3.71% | -1.87% |
| EPS Basic | 71.23% | 59.26% | 47.60% | 40.21% | 33.00% |
| Normalized Basic EPS | 70.34% | 61.99% | 50.07% | 43.16% | 35.78% |
| EPS Diluted | 71.23% | 59.26% | 47.60% | 40.21% | 33.00% |
| Normalized Diluted EPS | 70.34% | 61.99% | 50.07% | 43.16% | 35.78% |
| Average Basic Shares Outstanding | 144.00% | 111.85% | 84.81% | 79.87% | 57.60% |
| Average Diluted Shares Outstanding | 144.00% | 111.85% | 84.81% | 79.87% | 57.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |